| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Advances in cancer research dissemination through the pandemic and beyond
|
Desai, A.
|
|
|
32 |
6 |
p. 689-693
|
artikel
|
| 2 |
Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation
|
Thomas, F.
|
|
|
32 |
6 |
p. 810-811
|
artikel
|
| 3 |
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
|
Grivas, P.
|
|
|
32 |
6 |
p. 787-800
|
artikel
|
| 4 |
Circulating tumor DNA in patients with metastatic prostate cancer treated with abiraterone acetate
|
Loriot, Y.
|
|
|
32 |
6 |
p. 694-695
|
artikel
|
| 5 |
Complete pathological and serological response to immunotherapy in a patient with MMR-deficient early rectal cancer
|
Tarpgaard, L.S.
|
|
|
32 |
6 |
p. 805-806
|
artikel
|
| 6 |
Corrigendum to ‘Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’
|
Heuser, M.
|
|
|
32 |
6 |
p. 821
|
artikel
|
| 7 |
Corrigendum to ‘VP1-2021: Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer’
|
Bachelot, T.
|
|
|
32 |
6 |
p. 820
|
artikel
|
| 8 |
Editorial Board
|
|
|
|
32 |
6 |
p. iii
|
artikel
|
| 9 |
IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy
|
Gutzmer, R.
|
|
|
32 |
6 |
p. 696-697
|
artikel
|
| 10 |
IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies
|
Barrios, D.M.
|
|
|
32 |
6 |
p. 736-745
|
artikel
|
| 11 |
Is impaired response to PD-1 blockers of high serum PD-1 patients related to immune complexes?
|
Daveri, E.
|
|
|
32 |
6 |
p. 814-816
|
artikel
|
| 12 |
Novel drugs, familiar interactions: ciprofloxacin may increase exposure to the RET inhibitor pralsetinib
|
Citarella, F.
|
|
|
32 |
6 |
p. 811-813
|
artikel
|
| 13 |
NTRK fusion in soft tissue sarcomas harboring MDM2/CDK4 amplification: three case reports
|
Brahmi, M.
|
|
|
32 |
6 |
p. 813-814
|
artikel
|
| 14 |
Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma
|
Rawson, R.V.
|
|
|
32 |
6 |
p. 766-777
|
artikel
|
| 15 |
Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer
|
Subbiah, V.
|
|
|
32 |
6 |
p. 817-819
|
artikel
|
| 16 |
PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study
|
Eichenauer, D.A.
|
|
|
32 |
6 |
p. 807-810
|
artikel
|
| 17 |
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
|
Moore, K.N.
|
|
|
32 |
6 |
p. 757-765
|
artikel
|
| 18 |
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial
|
Jayaram, A.
|
|
|
32 |
6 |
p. 726-735
|
artikel
|
| 19 |
Prospective evaluation of dietary and lifestyle pattern indices with risk of colorectal cancer in a cohort of younger women
|
Yue, Y.
|
|
|
32 |
6 |
p. 778-786
|
artikel
|
| 20 |
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
|
Bardia, A.
|
|
|
32 |
6 |
p. 746-756
|
artikel
|
| 21 |
Small cell lung cancer: a slightly less orphan disease after immunotherapy
|
Remon, J.
|
|
|
32 |
6 |
p. 698-709
|
artikel
|
| 22 |
Table of Contents
|
|
|
|
32 |
6 |
p. i-ii
|
artikel
|
| 23 |
The systemic treatment of recurrent ovarian cancer revisited
|
Baert, T.
|
|
|
32 |
6 |
p. 710-725
|
artikel
|
| 24 |
Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines
|
Vogel, A.
|
|
|
32 |
6 |
p. 801-805
|
artikel
|
Tijdschrift beschrijving